Angiochem to Present at Stifel Nicolaus 2011 Healthcare Conference

MONTREAL--(BUSINESS WIRE)-- Angiochem, Inc., a clinical stage biotechnology company, today announced that Jean Paul Castaigne, MD, President and CEO is scheduled to present at the Stifel Nicolaus 2011 Healthcare Conference at 2:05 p.m. ET on Wednesday, September 7, 2011, at the Four Seasons Hotel, Boston.

About Angiochem

Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough drugs that are leveraging the LRP-1 mediated pathway to cross the blood-brain barrier (BBB) to treat brain diseases. These new Engineered Peptide Compounds (EPiC) have the potential to address significant medical needs, many of which cannot be effectively addressed due to the fundamental physiological challenge the blood-brain barrier presents for therapeutic intervention. Angiochem is developing a deep and broad product pipeline, including small molecules and biologics, for the potential treatment of a wide range of CNS diseases, including brain cancer, neurodegenerative and metabolic diseases, pain, and many others. Founded in 2003, Angiochem maintains headquarters in Montreal, Canada. For additional information about the Company, please visit


Media Contact:
The Yates Network
Gina Nugent, 617-460-3579
Business Development Contact:
Angiochem, Inc.
Catherine Gagnon, 514-788-7800 x204

KEYWORDS:   North America  Canada

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Mental Health  Pharmaceutical  Other Health  Research  Science


Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.